NIH-funded researchers have developed advanced gene delivery systems for precise targeting of brain and spinal cord cells. These systems, using modified adeno-associated viruses (AAVs), enable targeted gene therapy for various neurological disorders. The toolkit includes dozens of delivery systems for different cell types and AI-powered software to identify genetic switches. This breakthrough allows for more accurate research and potential treatments for conditions like ALS, Parkinson's, and Alzheimer's, significantly advancing our understanding of the brain.

Prepared by Olivia Bennett and reviewed by editorial team.